Pricing Log in Create free account
Friday 6 November 2026 Export VRTX’s income statement to Excel — free account

Vertex Pharmaceuticals Incorporated

VRTX Healthcare Biotechnology

Vertex Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.0 billion, up 8.90% from fiscal 2024.

Revenue
+11.9%
EPS
−39.2%
Free cash flow
−52.1%

Quarter to September 2026, against a year earlier

547.00 4.50 +0.83%
Market cap
$137.5B
P/E
34.6×
Fwd P/E
33.2×
Dividend yield
—
F-score
8/9
Altman Z
12.06
Beneish M
−2.17
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Vertex Pharmaceuticals Incorporated (VRTX) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, Vertex Pharmaceuticals Incorporated (VRTX) trades at a EV/Sales of 10.4×. Over the past ten years it has ranged from 5.5× (October 2021) to 53.8× (August 2015); the current reading is higher than 44% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 9.1× 2.65%
FY2024 8.9× (7.81%)
FY2023 9.7× 36.52%
FY2022 7.1× 7.47%
FY2021 6.6× (26.48%)
FY2020 9.0× (29.96%)
FY2019 12.8× (2.20%)
FY2018 13.1× (11.68%)
FY2017 14.8× 42.69%
FY2016 10.4× (64.36%)

Quarterly newest first

Period EV/Sales Change
Sep 2026 10.0× 6.57%
Jun 2026 9.4× 7.94%
Mar 2026 8.7× (4.55%)
Dec 2025 9.1× 13.75%
43 more quarters

Against its own ten years

Low 5.5× High 53.8×
Ten-year median 11.2×
Current reading's percentile 48

EV/Sales against peers

Company EV/Sales
REGN Regeneron Pharmaceuticals, Inc. compare 5.1×
ONC BeOne Medicines Ltd. - Sponsored ADR compare 5.9×
GMAB Genmab A/S Sponsored ADR compare 8.7×
ARGX argenex SE compare 8.9×
VRTX Vertex Pharmaceuticals Incorporated 10.4×
RPRX Royalty Pharma PLC compare 14.6×
MRNA Moderna, Inc. compare 41.1×
RVMD Revolution Medicines, Inc. compare 172×
ROIV Roivant Sciences Ltd. compare 3,061×
Biotechnology industry median 9.0×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on VRTX